Based on this finding, cenicriviroc (CVC), a CCR2-CCR5 dual antagonist, was expected to improve NASH and NAFLD and was tested in clinical trials (88). This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.